Abstract

Emerging medical biotechnology, with its dual‐use nature, presents both unprecedented opportunities and challenges for human society. As we benefit from technological innovation, it is crucial for Chinese academics and policymakers to effectively identify and address potential risks. However, the current framework for evaluating dual‐use research faces multiple challenges, including difficulties in identifying dual‐use issues, a lack of consideration for broader impacts in assessments, and a lack of consensus on balancing benefits and risks. Furthermore, inadequacies in the review mechanism, such as uneven progress among institutions, insufficient review capabilities, and lacking specialized knowledge among assessment personnel, hamper the effectiveness of evaluation efforts. This article aims to explore these challenges and propose practical recommendations for strengthening the evaluation and governance mechanisms of dual‐use research. By effectively mitigating the risks associated with dual‐use research, it facilitates the promotion of responsible scientific progress in emerging medical biotechnologies in China and internationally.